Effect of Lactobacillus rhamnosus and Diclofenac with Curcumin for neuronal restoration and repair against Scopolamine induced Dementia in Zebrafish (Danio rerio)
{"title":"Effect of Lactobacillus rhamnosus and Diclofenac with Curcumin for neuronal restoration and repair against Scopolamine induced Dementia in Zebrafish (Danio rerio)","authors":"Sonali Pande, Chirag Patel","doi":"10.2174/1573408019666230508155702","DOIUrl":null,"url":null,"abstract":"\n\nClinical studies have already revealed the ubiquitous neuroprotective role of curcumin in neuronal deterioration, but it cannot be used alone due to its truncated bioavailability. Currently, many such approaches are functional, which overcome this issue either by increasing the solubility or absorption. These approaches carry a costlier treatment. One more tactic is present but less focused i.e., by limiting the intestine and liver enzymatic metabolism; by this approach, curcumin will be more available for its beneficial outcome.\n\n\n\nThe goal of this study was to evaluate the impact of Lactobacillus rhamnosus and diclofenac on the neuroprotective effects of curcumin against scopolamine-induced dementia.\n\n\n\nPhysical parameters involved a novel tank test, T maze test, whereas neurochemical parameters include brain oxidative stress and acetylcholinesterase (Ache) inhibition activity in a zebrafish dementia model.\n\n\n\nOur results demonstrated that curcumin with Lactobacillus rhamnosus and diclofenac significantly (p<0.05) reduced anxiety, memory deficits, and brain oxidative stress compared to the alone curcumin-treated group.\n\n\n\nThis result approves that curcumin with L.rhamnosus and diclofenac have superior activity compared to curcumin alone. However, further clinical studies are needed to validate these findings\n","PeriodicalId":35405,"journal":{"name":"Current Enzyme Inhibition","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Enzyme Inhibition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573408019666230508155702","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Clinical studies have already revealed the ubiquitous neuroprotective role of curcumin in neuronal deterioration, but it cannot be used alone due to its truncated bioavailability. Currently, many such approaches are functional, which overcome this issue either by increasing the solubility or absorption. These approaches carry a costlier treatment. One more tactic is present but less focused i.e., by limiting the intestine and liver enzymatic metabolism; by this approach, curcumin will be more available for its beneficial outcome.
The goal of this study was to evaluate the impact of Lactobacillus rhamnosus and diclofenac on the neuroprotective effects of curcumin against scopolamine-induced dementia.
Physical parameters involved a novel tank test, T maze test, whereas neurochemical parameters include brain oxidative stress and acetylcholinesterase (Ache) inhibition activity in a zebrafish dementia model.
Our results demonstrated that curcumin with Lactobacillus rhamnosus and diclofenac significantly (p<0.05) reduced anxiety, memory deficits, and brain oxidative stress compared to the alone curcumin-treated group.
This result approves that curcumin with L.rhamnosus and diclofenac have superior activity compared to curcumin alone. However, further clinical studies are needed to validate these findings
期刊介绍:
Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.